Sep 28, 2022 07:12AM

Aug 22, 2022 07:12AM

Jun 8, 2022 07:12AM

May 9, 2022 07:15AM

Apr 19, 2022 05:05PM

Mar 17, 2022 07:15AM

Feb 17, 2022 07:12AM Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada

Jan 18, 2022 07:15AM

Dec 13, 2021 06:00AM

Nov 3, 2021 08:00AM

Nov 1, 2021 08:30AM

Oct 29, 2021 08:30AM

Oct 13, 2021 08:00AM

Oct 12, 2021 04:35PM Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial

Sep 13, 2021 08:00AM

Sep 8, 2021 08:00AM

Jul 6, 2021 06:00AM

Jun 23, 2021 12:16AM

Jun 3, 2021 08:04AM

May 5, 2021 10:01AM

Apr 27, 2021 01:41PM Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease

Apr 20, 2021 08:00AM

Apr 12, 2021 08:00AM

Mar 17, 2021 08:00AM

Mar 15, 2021 10:34AM

Mar 12, 2021 04:30PM

Mar 3, 2021 08:00AM

Jan 27, 2021 05:35PM Resverlogix Reschedules Update Webcast and Conference Call

Jan 18, 2021 07:30AM

Jan 12, 2021 08:00AM

Dec 22, 2020 05:17PM

Dec 22, 2020 07:30AM

Nov 20, 2020 06:28PM

Nov 12, 2020 08:00AM

Nov 2, 2020 07:30AM Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers

Oct 26, 2020 08:00AM

Oct 15, 2020 08:00AM

Oct 14, 2020 07:30AM

Oct 6, 2020 07:30AM

Oct 2, 2020 06:14PM

Sep 25, 2020 06:30PM

Sep 15, 2020 08:00AM Resverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research Reviews

Sep 11, 2020 08:18PM

Sep 8, 2020 08:00AM

Aug 28, 2020 06:30PM

Aug 14, 2020 06:19PM

Aug 4, 2020 08:00AM

Jul 28, 2020 06:00PM

Jul 22, 2020 07:00AM Resverlogix Secures One-Year Extension of Maturity Date of Debenture

Jun 22, 2020 07:00AM

322,968 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All